Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 September 2019 | Story Cornelius Hagenmeier (Director: UFS International Office)

The management of the University of the Free State (UFS) is deeply concerned about the xenophobic and afrophobic attacks presently occurring in our country. Xenophobia is the ‘fear and hatred of strangers or foreigners or of anything that is strange or foreign’ (Merriam-Webster Dictionary), whereas afrophobia can be understood as the ‘fear and hatred of the cultures and people of Africa’.

The UFS strongly condemns all forms of xenophobic and afrophobic actions and thought and expresses its solidarity with the members of the University community hailing from other regions of the African continent and the world. The UFS is committed to promoting diversity, social justice, inclusivity, and transformation. Its University community is united in its diversity. The UFS cherishes diversity as a catalyst for positive change, innovative research, and cutting-edge teaching and learning. Xenophobic actions, threats or statements will never be tolerated at the UFS. The UFS is committed to nurturing and entrenching a human-rights culture and advocating human rights both within the context of the University and beyond.

Xenophobia, afrophobia and discrimination jeopardise the process of internationalisation at the University. They limit the international and multicultural exposure of our students, which are important to achieve graduate attributes and specifically to develop students’ international and intercultural competence. The UFS is strategically strengthening its collaborations and partnerships in Africa and beyond. It recognises the positive force of diversifying the knowledge paradigms with which it interacts. International staff members, postdoctoral fellows, and students make a significant contribution to the academic project, scholarship traditions, and intellectual diversity of the University. The management of the UFS will do all in its power to ensure the wellbeing of all members of its international University community.



Released by:
Lacea Loader (Director: Communication and Marketing)
Telephone: + 27 51 401 2584 | +27 51 401 2454
Email: news@ufs.ac.za | loaderl@ufs.ac.za
Fax: +27 51 444 6393


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept